Halozyme Therapeutics (HALO) stock surged 6.43% in the premarket session on Wednesday, outperforming the broader markets. The biopharmaceutical company's shares soared after it raised its financial guidance for 2025, reflecting robust growth prospects across key metrics.

In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company significantly raised its 2025 outlook, projecting strong growth driven by increased royalty revenue and product sales.

For the full year 2025, Halozyme now expects total revenue to range between $1.15 billion and $1.23 billion, representing a year-over-year growth of 16% to 23%. The company attributed the anticipated revenue growth to the strong performance of its existing products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig.

Furthermore, Halozyme raised its 2025 guidance for adjusted EBITDA to $755 million to $805 million, reflecting a 24% to 32% increase compared to 2024. The company also forecast its non-GAAP diluted earnings per share to grow 21% to 30%, ranging from $4.95 to $5.35 in 2025.

In addition to the improved financial guidance, Halozyme announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.